NeuroSense Therapeutics logo

NeuroSense TherapeuticsNASDAQ: NRSN

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

Israel

IPO:

09 December 2021

Next earnings report:

N/A

Last dividends:

N/A

Next dividends:

N/A
$20.20 M
-70%vs. 3y high
25%vs. sector
-vs. 3y high
-vs. sector
-11.86
-232%vs. 3y high
3%vs. sector
-vs. 3y high
-vs. sector

Price

regular market | 8 min ago
$1.02-$0.00(-0.01%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

NRSN Latest News

NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND
prnewswire.com21 November 2024 Sentiment: -

CAMBRIDGE, Mass. , Nov. 21, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission
prnewswire.com28 October 2024 Sentiment: POSITIVE

Meeting discussion to focus on finalizing Phase 3 study design and NDA readiness, ensuring a clear regulatory path for submission based on trial success Parallel preparations in Canada: NeuroSense plans to submit its dossier in Q2 2025, with a regulatory decision on commercialization expected by Q1 2026 CAMBRIDGE, Mass. , Oct. 28, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates
prnewswire.com15 October 2024 Sentiment: POSITIVE

Dossier submission planned for Q2 2025; regulatory decision expected by Q1 2026 Estimated potential market opportunity: peak of $100M to $150M in annual revenue Company aims to expand approval efforts to additional global markets CAMBRIDGE, Mass. , Oct. 15, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstracts at the 2024 NEALS Annual Meeting
prnewswire.com07 October 2024 Sentiment: POSITIVE

CAMBRIDGE, Mass. , Oct. 7, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer's
prnewswire.com24 September 2024 Sentiment: POSITIVE

The Company's intellectual property now covers the combination, formulation, and method of use of PrimeC Patent protection extends through 2042, adding four additional years to PrimeC's IP umbrella CAMBRIDGE, Mass. , Sept. 24, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Announces Private Placement with Senior Management Participation at Premium to Market Price
prnewswire.com07 August 2024 Sentiment: POSITIVE

CAMBRIDGE, Mass. , Aug. 7, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression
prnewswire.com09 July 2024 Sentiment: POSITIVE

NeuroSense to submit the 12-month data to FDA to discuss path forward CAMBRIDGE, Mass. , July 9, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

This cheap biotech offers investors a play on ALS if trial data continues to impress
marketwatch.com02 July 2024 Sentiment: POSITIVE

NeuroSense Therapeutics Ltd.'s stock rose 6.5% Tuesday, as analysts cheered data from the biotech's late-stage trial of a treatment for the fatal disease amyotrophic lateral sclerosis, or ALS.

NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results
prnewswire.com24 June 2024 Sentiment: POSITIVE

Following positive 6-month clinical outcomes from phase 2b (PARADIGM) clinical trial, Company expects additional biomarker and 12-month clinical in the near term  CAMBRIDGE, Mass. , June 24, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense: A Hold Ahead Of Phase 2b ALS Data
Seeking Alpha06 October 2023 Sentiment: POSITIVE

NeuroSense Therapeutics will report Phase 2b trial data for its ALS drug candidate, PrimeC, in Q4 2023. Topline data of this trial may well be the company's most pivotal event since its IPO at the end of 2021. The company is also targeting Alzheimer's and Parkinson's with the same drug candidate under different names.

What type of business is NeuroSense Therapeutics?

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.

What sector is NeuroSense Therapeutics in?

NeuroSense Therapeutics is in the Healthcare sector

What industry is NeuroSense Therapeutics in?

NeuroSense Therapeutics is in the Biotechnology industry

What country is NeuroSense Therapeutics from?

NeuroSense Therapeutics is headquartered in Israel

When did NeuroSense Therapeutics go public?

NeuroSense Therapeutics initial public offering (IPO) was on 09 December 2021

What is NeuroSense Therapeutics website?

https://www.neurosense-tx.com

Is NeuroSense Therapeutics in the S&P 500?

No, NeuroSense Therapeutics is not included in the S&P 500 index

Is NeuroSense Therapeutics in the NASDAQ 100?

No, NeuroSense Therapeutics is not included in the NASDAQ 100 index

Is NeuroSense Therapeutics in the Dow Jones?

No, NeuroSense Therapeutics is not included in the Dow Jones index

When was NeuroSense Therapeutics the previous earnings report?

No data

When does NeuroSense Therapeutics earnings report?

Next earnings report date is not announced yet